1 / 11

The European Cardiac Risk Assessment Markers Markets: Analysis and Strategic Recommendations

The European Cardiac Risk Assessment Markers Markets: Analysis and Strategic Recommendations. Alex Wong Analyst Briefing 9 October 2002 London Office. Agenda. Introduction Segmentation Study areas Key market findings Key market drivers and restraints Forecast Revenue Distribution

carver
Download Presentation

The European Cardiac Risk Assessment Markers Markets: Analysis and Strategic Recommendations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The European Cardiac Risk Assessment Markers Markets: Analysis and Strategic Recommendations Alex Wong Analyst Briefing 9 October 2002 London Office

  2. Agenda • Introduction • Segmentation • Study areas • Key market findings • Key market drivers and restraints • Forecast Revenue Distribution • Summary 1

  3. Introduction Cardiac Risk Assessment: • CVD: leading cause of death • Flaws in current procedures • Considerable cost savings • Improve patient management 2

  4. Cardiac risk segmentation This report examines the following markers: • Activated Factor XII (AFT) • High-Sensitivity C-Reactive Protein (hsCRP) • Homocysteine (Hcy) • Brain natriuretic peptide (BNP) • pro-BNP • Lipoprotein a (Lpa) 3

  5. Countries under study Variations in: • uptake of cardiac risk markers • segment revenue sizes • key players’ market shares 4

  6. Bayer launch Hcy test. Dade Behring Hcy test launch likely Pro-BNP launched Bayer and Abbott BNP test launch likely BNP launched Hcy launched 5

  7. NP tests for CHF High cost of new tests Market Drivers Therapeutic monitoring Established vendor relations raises awareness 6

  8. Cheaper alternatives Cost containment Challenges & Restraints Patented markers: NPs Absence of country-specific guidelines Uncertainty of clinical utility 7

  9. Forecast Revenue Distribution 2001 2005 2001: $25m 1. Hcy 2. hsCRP 3. Lpa 2005: $60m 1. Hcy 2. BNP 3. hsCRP 8

  10. Summary • 2001 market worth $25 million • High level of growth forecast • Cardiac risk: improve patient management • BNP and pro-BNP driving growth 9

  11. Thank YouAny Questions? Contact us on: Email: enquiries@frost.com Tel: +44 (0) 20 7343 8383

More Related